TipRanks
Advertisement
Advertisement

MX:GSKN Stock Latest News

GSK’s ViiV Healthcare announces phase IIIb CROWN study met primary endpoint
The FlyGSK’s ViiV Healthcare announces phase IIIb CROWN study met primary endpoint
4d ago
GSK
Wave Life announces GSK’s selection of siRNA program to transition to GSK
PremiumThe Fly
Wave Life announces GSK’s selection of siRNA program to transition to GSK
10d ago
GSK
WVE
Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program
PremiumThe Fly
Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program
12d ago
GSK
SCYX
AN2 announces extension of funding for tuberculosis research collaboration
PremiumThe Fly
AN2 announces extension of funding for tuberculosis research collaboration
12d ago
GSK
ANTX
AnaptysBio price target lowered to $81 from $90 at Leerink
PremiumThe Fly
AnaptysBio price target lowered to $81 from $90 at Leerink
17d ago
GSK
ANAB
Trump Trade: U.S. announces deal with Denmark over Greenland’s security
PremiumThe FlyTrump Trade: U.S. announces deal with Denmark over Greenland’s security
19d ago
AZN
BMY
U.S. weighs allowing most pharma licensing deals with China, Reuters says
Premium
The Fly
U.S. weighs allowing most pharma licensing deals with China, Reuters says
22d ago
AZN
BMY
ViiV Healthcare continues partnership with Prevention Access Campaign
Premium
The Fly
ViiV Healthcare continues partnership with Prevention Access Campaign
23d ago
GSK
GSK enters agreement to acquire trispecific TCE from Chimagen
PremiumThe Fly
GSK enters agreement to acquire trispecific TCE from Chimagen
25d ago
GSK
GSK upgraded to Buy from Hold at Berenberg
PremiumThe Fly
GSK upgraded to Buy from Hold at Berenberg
25d ago
GSK
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
PremiumThe Fly
GSK presents results from phase I/II ARROS-1 trial evaluating Jideytro
27d ago
GSK
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
PremiumThe Fly
GSK licensor Hansoh announces ARTEMIS-008 phase III trial met primary endpoint
27d ago
GSK
GSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
PremiumThe FlyGSK announces Japan’s MHLW approved prefilled syringe presentation of Shingrix
1M ago
GSK
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
Premium
The Fly
GSK price target raised to 2,000 GBp from 1,860 GBp at HSBC
1M ago
GSK
GSK initiated with a Sector Perform at RBC Capital
Premium
The Fly
GSK initiated with a Sector Perform at RBC Capital
1M ago
GSK
GSK Boosts Q2 2026 Sales and Launches £1.9bn Accelerate Growth Programme to Fund Late-Stage R&D
PremiumCompany Announcements
GSK Boosts Q2 2026 Sales and Launches £1.9bn Accelerate Growth Programme to Fund Late-Stage R&D
1M ago
6K
GSK
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
PremiumRatings
GSK: Pipeline Optionality Recognized but Near-Term Data Gaps Keep Rating at Hold and Price Target Unchanged at 2,350 GBp
1M ago
GSK
Hutchmed, GSK enter HMPL-A830 commercialization agreement
PremiumThe Fly
Hutchmed, GSK enter HMPL-A830 commercialization agreement
1M ago
GSK
HCM
GSK presents phase II data from mRNA flu vaccine candidate
PremiumThe Fly
GSK presents phase II data from mRNA flu vaccine candidate
1M ago
GSK
GSK’s ViiV Healthcare announces FDA approval of Tivicay PD
PremiumThe FlyGSK’s ViiV Healthcare announces FDA approval of Tivicay PD
2M ago
GSK
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
Premium
The Fly
GSK price target raised to 1,900 GBp from 1,750 GBp at Morgan Stanley
2M ago
GSK
AnaptysBio price target lowered to $70 from $75 at TD Cowen
Premium
The Fly
AnaptysBio price target lowered to $70 from $75 at TD Cowen
2M ago
GSK
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >